OBI Pharma (4174) - Cash Flow Conversion Efficiency

Latest as of June 2026: -0.132x

Based on the latest financial reports, OBI Pharma (4174) has a cash flow conversion efficiency ratio of -0.132x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-290.40 Million ≈ $-9.15 Million USD) by net assets (NT$2.19 Billion ≈ $69.14 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 4174 company net worth for the company's overall valuation and market capitalisation.

OBI Pharma - Cash Flow Conversion Efficiency Trend (2011–2025)

This chart illustrates how OBI Pharma's cash flow conversion efficiency has evolved over time, based on yearly financial data.

OBI Pharma Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of OBI Pharma ranked by their cash flow conversion efficiency. Explore 4174 cash flow quality index to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
MFS High Income Municipal Closed Fund NYSE:CXE	0.024x
Equillium Inc NASDAQ:EQ	-0.273x
Topower Co Ltd TWO:3226	0.035x
Distribuidora de Gas Cuyana SA BA:DGCU2	0.061x
Genovate Biotechnology Co Ltd TWO:4130	0.012x
Hansae Yes24 KO:016450	0.105x
Hwaseung Enterprise Co Ltd KO:241590	0.018x
Jw Life Science Corp KO:234080	0.065x

Annual Cash Flow Conversion Efficiency for OBI Pharma (2011–2025)

The table below shows the annual cash flow conversion efficiency of OBI Pharma from 2011 to 2025. View OBI Pharma stock quote for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	NT$2.73 Billion ≈ $85.86 Million	NT$-2.02 Billion ≈ $-63.65 Million	-0.741x	-94.89%
2024-12-31	NT$4.82 Billion ≈ $151.87 Million	NT$-1.83 Billion ≈ $-57.77 Million	-0.380x	-13.99%
2023-12-31	NT$4.95 Billion ≈ $156.06 Million	NT$-1.65 Billion ≈ $-52.08 Million	-0.334x	-26.42%
2022-12-31	NT$6.14 Billion ≈ $193.32 Million	NT$-1.62 Billion ≈ $-51.03 Million	-0.264x	+4.01%
2021-12-31	NT$3.87 Billion ≈ $121.95 Million	NT$-1.06 Billion ≈ $-33.54 Million	-0.275x	+17.34%
2020-12-31	NT$4.84 Billion ≈ $152.42 Million	NT$-1.61 Billion ≈ $-50.71 Million	-0.333x	-65.38%
2019-12-31	NT$5.20 Billion ≈ $163.96 Million	NT$-1.05 Billion ≈ $-32.98 Million	-0.201x	-4.12%
2018-12-31	NT$4.47 Billion ≈ $140.94 Million	NT$-864.31 Million ≈ $-27.23 Million	-0.193x	+11.67%
2017-12-31	NT$5.06 Billion ≈ $159.43 Million	NT$-1.11 Billion ≈ $-34.87 Million	-0.219x	-60.41%
2016-12-31	NT$6.16 Billion ≈ $194.10 Million	NT$-840.10 Million ≈ $-26.47 Million	-0.136x	-163.20%
2015-12-31	NT$7.18 Billion ≈ $226.34 Million	NT$-372.20 Million ≈ $-11.73 Million	-0.052x	+83.89%
2014-12-31	NT$1.44 Billion ≈ $45.49 Million	NT$-464.22 Million ≈ $-14.63 Million	-0.322x	-495.51%
2013-12-31	NT$1.93 Billion ≈ $60.78 Million	NT$-104.16 Million ≈ $-3.28 Million	-0.054x	+61.92%
2012-12-31	NT$829.77 Million ≈ $26.14 Million	NT$-117.64 Million ≈ $-3.71 Million	-0.142x	+85.82%
2011-12-31	NT$508.44 Million ≈ $16.02 Million	NT$-508.22 Million ≈ $-16.01 Million	-1.000x	--

About OBI Pharma

TWO:4174 Taiwan Biotechnology

Market Cap

$115.04 Million

NT$3.65 Billion TWD

Market Cap Rank

#18749 Global

#1015 in Taiwan

Share Price

NT$27.75

Change (1 day)

+4.13%

52-Week Range

NT$23.25 - NT$50.50

All Time High

NT$743.00